340 related articles for article (PubMed ID: 25483668)
1. Production and evaluation of a recombinant subunit vaccine against botulinum neurotoxin serotype B using a 293E expression system.
Yu Y; Shi D; Liu S; Gong ZW; Wang S; Sun Z
Hum Vaccin Immunother; 2015; 11(2):468-73. PubMed ID: 25483668
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of candidate subunit vaccine against botulinum neurotoxin serotype B.
Shi DY; Chen BY; Mao YY; Zhou G; Lu JS; Yu YZ; Zhou XW; Sun ZW
Hum Vaccin Immunother; 2019; 15(3):755-760. PubMed ID: 30433836
[TBL] [Abstract][Full Text] [Related]
3. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D.
Stahl C; Unger L; Mazuet C; Popoff M; Straub R; Frey J
Vaccine; 2009 Sep; 27(41):5661-6. PubMed ID: 19646409
[TBL] [Abstract][Full Text] [Related]
4. Pentavalent replicon vaccines against botulinum neurotoxins and tetanus toxin using DNA-based Semliki Forest virus replicon vectors.
Yu YZ; Liu S; Ma Y; Gong ZW; Wang S; Sun ZW
Hum Vaccin Immunother; 2014; 10(7):1874-9. PubMed ID: 25424795
[TBL] [Abstract][Full Text] [Related]
5. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
Yu Y; Yu J; Li N; Wang S; Yu W; Sun Z
Vaccine; 2009 Oct; 27(44):6148-53. PubMed ID: 19712769
[TBL] [Abstract][Full Text] [Related]
6. Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.
White DM; Pellett S; Jensen MA; Tepp WH; Johnson EA; Arnason BG
Infect Immun; 2011 Aug; 79(8):3388-96. PubMed ID: 21576339
[TBL] [Abstract][Full Text] [Related]
7. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
[TBL] [Abstract][Full Text] [Related]
10. Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant.
Ma Y; An HJ; Wei XQ; Xu Q; Yu YZ; Sun ZW
Hum Vaccin Immunother; 2013 Feb; 9(2):242-9. PubMed ID: 23291932
[TBL] [Abstract][Full Text] [Related]
11. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
Gao YL; Gao S; Kang L; Nie C; Wang JL
Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
[TBL] [Abstract][Full Text] [Related]
13. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
[TBL] [Abstract][Full Text] [Related]
14. Preparation of egg yolk antibodies against BoNT/B and their passive protection in mouse models.
You Z; Yang H; Xin W; Kang L; Gao S; Wang J; Zhang T; Wang J
Hum Vaccin Immunother; 2014; 10(8):2321-7. PubMed ID: 25424938
[TBL] [Abstract][Full Text] [Related]
15. Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
Henkel JS; Tepp WH; Przedpelski A; Fritz RB; Johnson EA; Barbieri JT
Vaccine; 2011 Oct; 29(44):7688-95. PubMed ID: 21839134
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant.
Li N; Yu YZ; Yu WY; Sun ZW
Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):211-9. PubMed ID: 21284488
[TBL] [Abstract][Full Text] [Related]
17. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
[TBL] [Abstract][Full Text] [Related]
18. Alternative vaccination against equine botulism (BoNT/C).
Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
[TBL] [Abstract][Full Text] [Related]
19. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
[TBL] [Abstract][Full Text] [Related]
20. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A.
Liu FJ; Shi DY; Mao YY; Xiong XH; Lu JS; Pang XB; Dong XJ; Yang ZX; Yu YZ
Vaccine; 2020 Mar; 38(14):2978-2983. PubMed ID: 32113807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
